治疗寻常痤疮新药:trifarotene  

A new drug in treatment of acne vulgaris:trifarotene

作　　者：马琳 王楚婷 张勇[1] MA Lin;WANG Chu-ting;ZHANG Yong(School of Chemical and Pharmaceutical Engineering,Hebei University of Science and Technology,Shijiazhuang HEBEI 050018,China)

机构地区：[1]河北科技大学化学与制药工程学院,河北石家庄050018

出　　处：《中国新药与临床杂志》2024年第11期820-824,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：寻常痤疮是皮肤科最常见的皮肤病之一,类视黄醇类药物是治疗该疾病常用的临床药物。trifarotene采用具有视黄酸受体亚型选择性的三芳基骨架化合物CD437为先导化合物,通过受体结构的优化方式衍生而来,由于对视黄酸受体-γ(RAR-γ)具有高度选择性,被称作第四代类视黄醇类抗痤疮药。2019年10月,trifarotene获美国食品和药物管理局批准上市,用于治疗9岁及以上年龄患者的寻常痤疮。临床试验表明,trifarotene治疗寻常痤疮安全、有效,患者耐受性好,具有较好的临床应用前景。Acne vulgaris is one of the most common skin diseases in dermatology.Retinoids are commonly used in the treatment of this disease.Trifarotene is derived from CD437,a triaryl skeleton lead compound with retinoic acid receptor subtype selectivity,after the optimization of receptor structure.It is called the fourth generation retinoic acid anti-acne drug because of its high selectivity for retinoic acid γ receptor(RAR-γ).In October 2019,trifarotene was approved by the U.S.Food and Drug Administration for the treatment of acne vulgaris in patients aged 9 and above.Clinical trials have shown that trifarotene is safe,effective and well tolerated in the treatment of acne vulgaris,which has a good clinical application prospect.

关 键 词：trifarotene 寻常痤疮 类视黄醇 视黄酸受体-γ 

分 类 号：R986[医药卫生—药品]